By JULIE EGGINGTON, EKATERINA CLEARY & LEEZA OSIPENKO
When CMS issued its Request for Data below the Complete Rules to Uncover Suspicious Healthcare (CRUSH) initiative in February, it zeroed in on a long-festering downside: fraud, waste, and abuse in laboratory testing, particularly in genetic and molecular diagnostics.
The laboratory trade will reply. And when it does, its arguments will sound polished, acquainted, and deeply reassuring. They may even be both disingenuous or unproven.
If policymakers need this effort to succeed, they need to be ready to deal with three claims which have lengthy shielded problematic practices from significant oversight.
Declare 1: Fraud, waste and abuse is proscribed to a couple unhealthy actors
Count on labs to argue that fraud, waste, and abuse is uncommon, remoted, and already addressed via enforcement actions. The narrative will function a handful of egregious instancesintroduced as outliers in an in any other case reliable ecosystem.
However the issue shouldn’t be just a few rotten apples. It’s the orchard’s design.
Take “code stacking” for instance, by which laboratories invoice a number of particular person genetic check codes relatively than a single panel code, typically inflating reimbursement. In one evaluationlaboratories used between 1 and 12 billing codes for hereditary most cancers panels with the identical indications for testing, with estimated common expenses starting from $679 to $8,589 for ostensibly comparable assessments. The repetition of those behaviors throughout corporations suggests systemic incentives, not remoted misconduct.
Ample Medicare billing information, whistleblower instancesand Division of Justice settlements level to patternsnot anomalies: high-volume genetic panels ordered with little scientific justification, molecular pathology assessments billed below seize bag and overly permissive billing codesand aggressive advertising and affected person harvesting practices focusing on susceptible populations.
A key driver is opacity. Many laboratory-developed assessments (LDTs) are marketed below related or equivalent names regardless of significant variations in design, accuracy, and supposed use. To a clinician or payer, they seem interchangeable. In actuality, they don’t seem to be.
This naming ambiguity permits lower-quality assessments to journey the coattails of better-validated ones, whereas nonetheless commanding reimbursement. Fraud, on this context, shouldn’t be all the time a dramatic act. It’s typically embedded in routine billing.
Declare 2: Precision drugs superior by genetics is price the fee as a result of improved affected person outcomes
The second argument will enchantment to aspiration. Labs will emphasize that genetic testing is the spine of precision drugs and due to this fact a worthwhile funding for CMS, regardless of the ballooning prices.
Laboratory lobbyists and trade teams will use the ‘age of precision drugs’ argument to justify the truth that genetic testing is now costing Medicare nearly as a lot as all different outpatient laboratory testing mixed. In the latest evaluation from 2024 Medicare dategenetic assessments accounted for 43% ($3.6 billion) of whole Medicare outpatient laboratory spending, regardless of representing solely 5% of all Medicare outpatient laboratory assessments carried out.
There may be some fact right here to the worth of genetic assessments. Chosen genetic assessments have demonstrated clear scientific utility, enhancing analysis, or guiding therapy that has resulted within the extension of life.
However the leap from “some” assessments resulting in improved affected person outcomes to “most” assessments resulting in improved affected person outcomes is the place the argument breaks down.
The proof base for a lot of marketed genetic and molecular assessments stays skinny, heterogeneous, or completely absent. Scientific utility, within the uncommon situations the place customers or a check developer has demonstrated it, is commonly prolonged as a halo over different assessments from totally different labs providing equally marketed assessments. Whereas the me-too unproven assessments share practical branding and billing codes with the confirmed check, they typically differ in methodology or efficiency in nontransparent methods. Briefly, as a result of inherent variations in methodologies, the me-too assessments might not enhance affected person outcomes on the identical effectiveness because the confirmed check, and maybe by no means.
This isn’t precision drugs. It’s approximation at scale.
For policymakers, the excellence issues. With out proof {that a} check informs scientific choices in a approach that improves well being, its worth to Medicare and Medicaid stays unproven.
If labs want to declare that their assessments save or enhance lives, they need to exhibit it for every distinct check, whether or not or not it’s market chief assessments or the me-too assessments.
Declare 3: Oversight on labs slows innovation on the expense of lives saved
Lastly, anticipate labs to difficulty a warning: stricter oversight of labs’ affected person recruitment and billing practices will sluggish innovation, delay entry to cutting-edge diagnostics, and in the end hurt sufferers.
This argument rests on a crucial assumption that has not been established, specifically that the present quantity and acceleration of precision drugs associated laboratory testing is delivering life-saving profit at scale.
In lots of instances, that proof doesn’t exist, or exists on the contrary.
Innovation in healthcare shouldn’t be outlined by the variety of assessments medical doctors order for sufferers, or the growing complexity and expense of molecular pathology testing, however by their impression on affected person outcomes. Requiring that the precise sufferers obtain the precise assessments (which have confirmed utility), on the proper time, doesn’t inherently suppress innovation; it helps distinguish between significant advances and the noise
Nicely documented efforts by some genetics labs to recruit as many sufferers as doable leads to the dilution of the true worth of genetic testing. Even when, for instance, a most cancers genetic testing laboratory has a check with confirmed scientific utility for sufferers with sure cancers, testing sufferers with out the related cancers would dilute its measurable scientific utility. And because of the existence of false positives in diagnostics, testing sufferers recruited inappropriately may in the end hurt extra sufferers than the check helps.
Moreover, the absence of billing requirements can distort innovation. When reimbursement is accessible with out strong proof necessities, the market rewards proliferation over validation. With out oversight, high-quality assessments should compete with lower-cost, lower-evidence alternate options which are marketed as equal or higher than the confirmed assessments.
Stricter oversight of laboratories affected person recruitment and requests for reimbursement would offer CMS alternative to make sure that the objectives of precision drugs are achieved. It will not halt innovation. It will redirect it towards demonstrable worth.
A path ahead
If CMS needs to scale back fraud, waste, and abuse in laboratory testing, it ought to focus much less on chasing particular person unhealthy actors – which is proving to be an infinite sport of whack-a-mole – and extra on correcting structural weaknesses.
That begins with transparency. Assessments that differ in design or efficiency mustn’t share indistinguishable names in billing programs. Clear differentiation would make it tougher for lower-quality assessments to masquerade as established ones.
It additionally requires proof self-discipline. Protection and reimbursement needs to be tied to demonstrated scientific utility on the check degree, not inferred from category-level proof.
The CRUSH RFI presents a chance to reset expectations. The laboratory trade will make its case. CMS needs to be able to look previous the acquainted narratives and ask a less complicated query: not whether or not a check may advance drugs, however whether or not it does.
Julie Eggington is CEO of the Heart for Genomic Interpretation and founding father of Grandview Consulting. Ekaterina Cleary is a Information Scientist and Leeza Osipenko is CEO at Consilium Scientific, the place she leads the event of This publish is a part of their work at Evimetera quantitative framework for evaluating the power of scientific proof supporting breakthrough medical units and diagnostics, funded by Arnold Ventures.
